Press Releases

Press Releases

Jan 22, 2020	Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 10, 2020	Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 09, 2020	Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 07, 2020	Ionis' neurological franchise marks year of achievement
Jan 06, 2020	Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
Jan 02, 2020	New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

Investor contact